N-acetylcysteine in COPD may be beneficial, but for whom?

The Lancet Respiratory Medicine

Volumn 2, Issue 3, 2014, Pages 166-167

  Cazzola, Mario ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; GLUTATHIONE; PLACEBO; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; MUCOLYSIS; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK REDUCTION; TREATMENT OUTCOME;

ACETYLCYSTEINE; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84895782525     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70294-7     Document Type: Note

References (16)

1. Sutherland ER, Crapo JD, Bowler RP N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD 2006, 3:195-202.
2. Franssen FM, Spruit MA, Wouters EF Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011, 6:493-501.
3. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre National Clinical Guideline Centre, (accessed Dec 21, 2013). http://guidance.nice.org.uk/CG101/Guidance/pdf/English.
4. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease (GOLD), (accessed Dec 21, 2013). http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html.
5. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 2007, 20:9-22.
6. Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013, 144:106-118.
7. De Backer J, Vos W, Van Holsbeke C, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J Chron Obstruct Pulmon Dis 2013, 8:569-579.
8. Zheng J-P, Wen F-Q, Bai C-X, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014, published online Jan 30. http://dx.doi.org/10.1016/S2213-2600(13)70286-8.
9. Miravitlles M, Calle M, Soler-Cataluña JJ Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronconeumol 2012, 48:86-89.
10. Anderson D, Macnee W Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis 2009, 4:321-335.
11. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005, 365:1552-1560.
12. Burgunder JM, Varriale A, Lauterburg BH Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989, 36:127-131.
13. Aitio ML N-acetylcysteine-passe-partout or much ado about nothing?. Br J Clin Pharmacol 2006, 61:5-15.
14. De Benedetto F, Aceto A, Dragani B, et al. Long-term oral N-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005, 18:41-47.
15. Grandjean EM, Berthet P, Ruffman R, Leuenberger P Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind placebo-controlled clinical trials. Clin Ther 2000, 22:209-221.
16. Poole P, Black PN, Cates CJ Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 8. CD001287.